Literature DB >> 18583161

Smoking reduces serum levels of lamotrigine.

Claus Reinsberger1, Thomas Dorn, Günter Krämer.   

Abstract

The influence of smoking on lamotrigine (LTG) serum levels in 44 patients with epilepsy treated with LTG in monotherapy was examined. Fifteen patients were smokers (range: three cigarettes per month -- three packages per day) and 29 were non-smokers. Analyzing 204 samples, smokers had a significantly lower serum level-to-dose ratio than non-smokers (0.0657mmolmg/l (smokers) vs. 0.0785mmolmg/l (non-smokers)) (p=0.0014). Analyzing only male patients, the same relationship with an almost equally high level of significance could be demonstrated (p=0.008). Our data indicate that the demonstrated effect of smoking on LTG metabolism is likely to be mediated via UDPGT2B7, as LTG is not a substrate of cytochrome P450 isoenzymes and UDPGT1A4 activity may not be affected by nicotine, but the exact mechanism underlying the demonstrated effect remains uncertain. These findings are likely to be independent from hormonal changes, as they could also be reproduced in the group of male patients. Therefore, the effect of smoking on blood levels of LTG has to be taken into account in the evaluation of treatment with this drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583161     DOI: 10.1016/j.seizure.2008.05.009

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  4 in total

1.  Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust.

Authors:  Petrina Douglas-Hall; Olubanke Dzahini; Fiona Gaughran; Ahmed Bile; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

2.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

3.  Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.

Authors:  Kazuyuki Inoue; Yoshiaki Yamamoto; Eri Suzuki; Toshiki Takahashi; Akiko Umemura; Yukitoshi Takahashi; Katsumi Imai; Yushi Inoue; Keita Hirai; Daiki Tsuji; Kunihiko Itoh
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

Review 4.  Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review).

Authors:  Sergej Nadalin; Hrvoje Jakovac; Vjekoslav Peitl; Dalibor Karlović; Alena Buretić-Tomljanović
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.